DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA604317
Title:
Exploring AR-NFkappaB/p52-Targeted Inhibitors as Novel Therapy Against Castration-Resistant Prostate Cancer Progression
Descriptive Note:
Final rept. 15 Aug 2012-28 Feb 2014
Corporate Author:
WISCONSIN UNIV MADISON
Report Date:
2014-05-01
Pagination or Media Count:
21.0
Abstract:
The goal of this research was to verify the specificity of the inhibition of androgen receptor AR NFkBp52 interaction by small molecule ARp52 inhibitors selected from prior high throughput screen in cell culture and ARp52 activity assays, and determine the efficacy of the compounds against castration resistant prostate cancer CRPCa cell xenograft growth. Data from this research should establish the AR-p52 interaction as a viable new target for preventing progression to CRPCa and identify lead compounds to be further developed for preclinical toxicity testing and clinical trials for PCa that fall beyond the scope of this proposal. Cell culture studies identified a lead compound with IC50 of 5 956M against both androgen-dependent and independent PCa cell growth that involves reduction in CyclinD1, and significant inhibition of AR transcriptional activity as measured by PSA mRNA as well as inhibition of AR and p52 translocation to nucleus. Efficacy of the lead compound in an oral regimen against CRPCa xenograft tumor development and progression was established. Thus the lead compound shows evidence of specificity for AR-p52 interaction and efficacy against CRPCa. These data help establish AR-p52 interaction as a viable new target for PCa therapy and identify a lead compound that can be further developed toward clinical application as a new therapeutic agent to prevent progression of CRPCa.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
